{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:05:56Z","timestamp":1784541956668,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T00:00:00Z","timestamp":1620518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T00:00:00Z","timestamp":1620518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1245\/s10434-021-10062-6","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T16:02:27Z","timestamp":1620576147000},"page":"7912-7920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Disease-free Interval Is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor"],"prefix":"10.1245","volume":"28","author":[{"given":"Thomas L.","family":"Sutton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett S.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Billingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett C.","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Corless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skye C.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,9]]},"reference":[{"issue":"10","key":"10062_CR1","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S0046-8177(99)90040-0","volume":"30","author":"M Miettinen","year":"1999","unstructured":"Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999;30(10):1213\u201320.","journal-title":"Hum Pathol"},{"key":"10062_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1146\/annurev.pathmechdis.3.121806.151538","volume":"3","author":"CL Corless","year":"2008","unstructured":"Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008;3:557\u201386.","journal-title":"Annu Rev Pathol"},{"issue":"12","key":"10062_CR3","doi-asserted-by":"publisher","first-page":"e184060","DOI":"10.1001\/jamaoncol.2018.4060","volume":"4","author":"CP Raut","year":"2018","unstructured":"Raut CP, Espat NJ, Maki RG, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol. 2018;4(12):e184060.","journal-title":"JAMA Oncol"},{"issue":"9669","key":"10062_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","volume":"373","author":"RP Dematteo","year":"2009","unstructured":"Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097\u2013104.","journal-title":"Lancet"},{"issue":"10","key":"10062_CR5","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1245\/s10434-020-08869-w","volume":"27","author":"EZ Keung","year":"2020","unstructured":"Keung EZ, Raut CP, Rutkowski P. The landmark series: systemic therapy for resectable gastrointestinal stromal tumors. Ann Surg Oncol. 2020;27(10):3659\u201371.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10062_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265\u201372.","journal-title":"JAMA"},{"issue":"3","key":"10062_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jamcollsurg.2014.02.037","volume":"219","author":"DA Bischof","year":"2014","unstructured":"Bischof DA, Kim Y, Blazer DG 3rd, et al. Surgical management of advanced gastrointestinal stromal tumors: an international multi-institutional analysis of 158 patients. J Am Coll Surg. 2014;219(3):439\u201349.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10062_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","volume":"231","author":"RP DeMatteo","year":"2000","unstructured":"DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51\u20138.","journal-title":"Ann Surg"},{"issue":"11","key":"10062_CR9","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/ans.13220","volume":"86","author":"GH Tan","year":"2016","unstructured":"Tan GH, Wong JS, Quek R, et al. Role of upfront surgery for recurrent gastrointestinal stromal tumours. ANZ J Surg. 2016;86(11):910\u20135.","journal-title":"ANZ J Surg"},{"issue":"8","key":"10062_CR10","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/bjs.10809","volume":"105","author":"WTA van der Graaf","year":"2018","unstructured":"van der Graaf WTA, Tielen R, Bonenkamp JJ, Lemmens V, Verhoeven RHA, de Wilt JHW. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. Br J Surg. 2018;105(8):1020\u20137.","journal-title":"Br J Surg"},{"issue":"3","key":"10062_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2015.62.9170","volume":"34","author":"H Joensuu","year":"2016","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol. 2016;34(3):244\u201350.","journal-title":"J Clin Oncol"},{"issue":"11","key":"10062_CR12","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1245\/s10434-015-4400-z","volume":"22","author":"AY Chok","year":"2015","unstructured":"Chok AY, Goh BK, Koh YX, et al. Validation of the MSKCC gastrointestinal stromal tumor nomogram and comparison with other prognostication systems: single-institution experience with 289 patients. Ann Surg Oncol. 2015;22(11):3597\u2013605.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10062_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(09)70242-6","volume":"10","author":"JS Gold","year":"2009","unstructured":"Gold JS, G\u00f6nen M, Guti\u00e9rrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10(11):1045\u201352.","journal-title":"Lancet Oncol"},{"issue":"10","key":"10062_CR14","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ejso.2011.06.005","volume":"37","author":"P Rutkowski","year":"2011","unstructured":"Rutkowski P, Bylina E, Wozniak A, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour\u2014the impact of tumour rupture on patient outcomes. Eur J Surg Oncol. 2011;37(10):890\u20136.","journal-title":"Eur J Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-10062-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10062-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:20:03Z","timestamp":1634329203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-10062-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,9]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10062"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-10062-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,9]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael Heinrich is a consultant for Blueprint Medicines, Deciphera Pharmaceuticals, Novartis, and Theseus. Thomas L. Sutton, Brett S. Walker, Kevin G. Billingsley, Brett C. Sheppard, Christopher L. Corless, and Skye C. Mayo have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}